[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infertility-assisted-reproductive-technology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infertility-assisted-reproductive-technology":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,49,74,126,154,176,212,236,263,289,315,338,369,394,422],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100643177","a-large-scale-prospective-cohort-study-was-conducted-to-explore-the-association-between-environmental-exposure-and-behavioral-factors-and-infertility-the-success-rate-of-assisted-reproductive-technology-100643177",false,"NCT07641387","A Large-scale, Prospective Cohort Study Was Conducted to Explore the Association Between Environmental Exposure and Behavioral Factors and Infertility (the Success Rate of Assisted Reproductive Technology)","Inclusion Criteria:\n\n* 1\\. Women aged 18 to 46 who use their own eggs or men aged 18 to 55 who use their own sperm; 2. Patients who meet the diagnostic criteria for infertility; 3. Clarify the medical history of persistent infertility for a certain period of time; 4. Voluntarily participate in the project and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Artificial insemination population with any of the following ARTs contraindications: a. Impairment of sperm and egg combination caused by fallopian tube factors on the female side. b. The female side suffers from acute infection of the reproductive and urinary system or sexually transmitted diseases. c. The female side suffers from genetic diseases, serious physical diseases, and mental and psychological disorders. d. There is a history of birth of babies with congenital defects and it is confirmed that it is caused by female factors. e. The female side is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. f. The female side has bad habits such as alcoholism and drug abuse.\n\n  2\\. First-generation test-tube baby and second-generation test-tube baby population with any of the following ARTs contraindications: a. Any party who provides gametes suffers from acute infection of the reproductive and urinary systems and sexually transmitted diseases or has bad habits such as alcoholism and drug abuse. b. Any party who provides gametes is exposed to teratogenic radiation, poisons, and drugs and is in the period of action. c. The couple who received embryo donation\u002Fegg donation suffers from acute infection of reproductive and urinary system and sexually transmitted diseases, or has bad habits such as alcoholism and drug abuse. d. The woman's uterus is not capable of pregnancy or has a serious physical disease that cannot withstand pregnancy.\n\n  3\\. No embryo transfer after egg retrieval; 4. Frozen embryo transfer is received more than 180 days after egg retrieval.","ALL","18 Years","55 Years",{"count":19,"type":20},5000,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim is to explore the reasons for the failure of assisted reproductive technology (ART) in infertile patients in Hunan Province and seek ways to improve the success rate of ART. The study will focus on how environmental exposure (such as environmental pollutants related to plastic products) and lifestyle and social factors affect the success rate of ART in infertile patients.\n\nIn order to explore these issues in depth, the study plans to collect 5,000 samples (male: female ratio 1:1), screen the research subjects from infertile patients who visited Xiangya Third Hospital in Changsha, Hunan Province, and establish a large-scale, prospective infertility patient cohort. By collecting multi-faceted information of the research subjects, including sociodemographic characteristics, lifestyle, basic health status, etc., and conducting long-term follow-up observations, the ART live birth situation of infertile patients is analyzed.\n\nIn terms of research methods, a multivariate analysis method will be used to explore the association between various factors and ART success rate, and a risk prediction model will be constructed. In addition, the study also hopes to clarify the specific reasons for the failure of infertile patients to receive ART, provide a scientific basis for clinical decision-making, and provide guidance for the formulation of environmental protection policies and the improvement of public reproductive health literacy.\n\nIn general, this study, through a large-scale, prospective cohort study, deeply explores the various factors that affect the success rate of ART in infertile patients, and strives to build a risk prediction model in order to improve the success rate of ART and bring more hope to infertile families.",[26,27,28],"Infertility","Infertility Assisted Reproductive Technology","Infertility (IVF Patients)",[30,31,32,33,34,35],"environmental pollutants","Assisted Reproductive Technology","prospective cohort","life-style","risk factor","social factor","RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":40},"2025-04-01",{"date":44,"type":20},"2035-04-01",{"name":46,"class":47},"The Third Xiangya Hospital of Central South University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":16,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100578829","quantifying-uterine-elastography-in-menstruating-women-100578829","NCT06816381","Quantifying Uterine Elastography in Menstruating Women","Characterizing Uterine and Ovarian Tissue Stiffness Via Shear Wave Elastography in Non-Infertile, Fertile, and Infertile Women With Normal Anatomy Across the Menstrual Cycle: A Pilot Study","QUEST","Group A\n\nInclusion Criteria:\n\n* Patients with normal menstrual cycles lasting 28-34 days\n* Patients with normal uterine anatomy\n* Patients with no prior pregnancy history including miscarriages, terminations, ectopic pregnancies, preterm deliveries, or full-term deliveries\n* Patient who have no known infertility (i.e. women who have not tried to conceive)\n\nExclusion Criteria:\n\n* BMI ≥ 35\n* Current use of intrauterine devices (IUDs), hormonal implants, or hormonal birth control medications. Participants on hormonal birth control interested in study participation may be included following one month of discontinuation of hormonal medication.\n* History of uterine surgery (i.e hysteroscopy, dilation and curettage, myomectomy)\n* History of ovarian surgery (i.e ovarian cystectomy, oophorectomy, removal of -endometrioma)\n* History of surgically-confirmed or clinically suspected endometriosis or ultrasound evidence of endometriosis (i.e endometrioma)\n* Currently present or surgically corrected uterine anomalies\n* Ultrasound evidence of or history of communicating hydrosalpinx\n* Ultrasound evidence of or history of leiomyomas\n* Ultrasound evidence of adenomyosis based on the Morphological Uterus Sonographic Assessment criteria (MUSA) (19)\n* Ultrasound evidence of ovarian pathology including mature teratoma\u002Fdermoid cyst, persistent functional cysts larger than 2 cm, or ovarian cancer.\n\nGroup B\n\nInclusion Criteria:\n\n* Patients with normal menstrual cycles lasting 28 days to 34 days.\n* Patients with normal uterine and ovarian anatomy (absence of gross pathology on screening visit ultrasound)\n* Patients with at least one prior full-term vaginal delivery with time to conception less than one year without the use of assisted reproductive technology.\n\nExclusion Criteria\n\n* BMI ≥ 35\n* Current use of intrauterine devices (IUDs), hormonal implants, or hormonal birth control medications. Participants on hormonal birth control interested in study participation may be included following one month of discontinuation of hormonal medication.\n* History of cesarean section\n* Patient who have no known secondary infertility (i.e. women who have not tried to conceive)\n* Diagnosis of secondary infertility (i.e women who have attempted pregnancy for 12 months without success)\n* History of uterine surgery (i.e hysteroscopy, dilation and curettage, myomectomy)\n* History of ovarian surgery (i.e ovarian cystectomy, oophorectomy, removal of endometrioma)\n* History of surgically-confirmed or clinically suspected endometriosis or ultrasound evidence of endometriosis (i.e endometrioma)\n* Currently present or surgically corrected uterine anomalies\n* Ultrasound evidence of or history of communicating hydrosalpinx\n* Ultrasound evidence of or history of leiomyomas\n* Ultrasound evidence of adenomyosis based on the Morphological Uterus Sonographic Assessment criteria (MUSA) (19)\n* Ultrasound evidence of ovarian pathology including mature teratoma\u002Fdermoid cyst, persistent functional cysts larger than 2 cm, or ovarian cancer.\n\nGroup C\n\nInclusion Criteria:\n\n* Patients with normal menstrual cycles lasting 28 days to 34 days.\n* Patients with normal uterine and ovarian anatomy (absence of gross pathology on screening visit ultrasound)\n* Patient with no prior pregnancy history including miscarriages, terminations, ectopic pregnancies, preterm deliveries, or full-term deliveries (i.e gravity equals zero).\n* Patient with diagnosis of primary infertility, with attempted conception for at least 12 months if younger than 35 years and attempted conception for at least 6 months if 35 years or older.\n\nExclusion Criteria\n\n* BMI ≥ 35\n* Current use of intrauterine devices (IUDs), hormonal implants, or hormonal birth control medications. Participants on hormonal birth control interested in study participation may be included following one month of discontinuation of hormonal medication.\n* History of three or more failed euploid embryo transfers\n* Severe male factor infertility including severe oligozoospermia and cryptozoospermia\n* History of uterine surgery (i.e hysteroscopy, dilation and curettage, myomectomy)\n* History of ovarian surgery (i.e ovarian cystectomy, oophorectomy, removal of endometrioma)\n* History of surgically-confirmed or clinically suspected endometriosis or ultrasound evidence of endometriosis (i.e endometrioma)\n* Currently present or surgically corrected uterine anomalies\n* Ultrasound evidence of or history of communicating hydrosalpinx\n* Ultrasound evidence of or history of leiomyomas\n* Ultrasound evidence of adenomyosis based on the Morphological Uterus Sonographic Assessment criteria (MUSA) (19)\n* Ultrasound evidence of ovarian pathology including mature teratoma\u002Fdermoid cyst, persistent functional cysts larger than 2 cm, or ovarian cancer.",true,"FEMALE","45 Years",{"count":61,"type":20},40,"OBSERVATIONAL","This study is aiming to characterize the elasticity of the female reproductive tract including the uterus, cervix and ovary using shear wave elastography at different times during the menstrual cycle and define the standard reference range of normal uterine and ovarian elasticity. By doing so, the potential of using shear wave elastography to diagnose and predict outcomes for patients seeking fertility treatment might be established.",[28,27],"2026-06-01",{"date":67,"type":40},"2026-06-03",{"date":69,"type":40},"2025-02-06",{"date":71,"type":20},"2027-12",{"name":73,"class":47},"Reproductive Medicine Associates of New Jersey",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":58,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":48},"100624079","biological-aging-hallmarks-guided-integrative-tcm-and-conventional-medicine-in-post-treatment-unexplained-female-infertility-100624079","NCT07404969","Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility","An Interventional Study Evaluating Telomere and Biological Aging Hallmarks Profiling to Guide an Integrative Traditional Chinese and Conventional Medicine Approach in Women With Post-Treatment Unexplained Infertility","TECMI","Inclusion Criteria:\n\n* Biological female participants aged 25 to 42 years.\n* Diagnosis of infertility defined as failure to conceive after at least 12 months of unprotected intercourse and\u002For repeated failure of assisted reproductive technologies (ART), including intrauterine insemination (IUI) and\u002For in vitro fertilization (IVF).\n* History of post-treatment unexplained or functionally idiopathic infertility, defined as persistent infertility despite adequate correction or management of identifiable reproductive conditions (e.g., endometriosis, polycystic ovary syndrome, hormonal imbalance, uterine factors).\n* Eligibility for natural conception attempts and\u002For assisted reproductive technologies according to routine clinical practice.\n* Willingness to undergo biological aging biomarker profiling, including leukocyte telomere analysis.\n* Ability and willingness to comply with study procedures, including the preconception integrative intervention and follow-up assessments.\n* Provision of written informed consent prior to participation.\n\nExclusion Criteria:\n\n* Current pregnancy or breastfeeding at the time of enrollment.\n* Known chromosomal abnormalities or genetic conditions directly impairing fertility (e.g., Turner syndrome).\n* Untreated severe male factor infertility precluding conception by natural or standard ART methods.\n* Active malignancy or history of cancer requiring systemic treatment within the past 5 years.\n* Severe systemic disease or medical condition contraindicating pregnancy or participation in ART (as determined by the treating physician).\n* Use of investigational drugs or participation in another interventional clinical trial that could interfere with the study outcomes.\n* Known hypersensitivity or contraindication to components of the integrative intervention, as determined by clinical assessment.\n* Any condition which, in the opinion of the investigator, would interfere with safe participation or interpretation of study results.","25 Years","42 Years",{"count":5,"type":20},[23],"The goal of this clinical trial is to determine whether telomere profiling and other biological aging hallmarks can help identify underlying mechanisms of persistent infertility in women with post-treatment unexplained infertility. The study also evaluates whether a personalized integrative treatment guided by these biomarkers can improve reproductive outcomes.\n\nThe study includes women aged 25 to 42 years who continue to experience infertility despite appropriate management of identifiable reproductive conditions and repeated attempts with assisted reproductive technologies (ART), such as intrauterine insemination (IUI) or in vitro fertilization (IVF).\n\nThe main questions this study aims to answer are:\n\n* Can telomere and biological aging hallmarks profiling identify a biological aging phenotype associated with infertility?\n* Can an integrative treatment guided by these profiles improve clinical pregnancy outcomes?\n\nParticipants will:\n\n* Undergo a baseline reproductive evaluation and blood-based assessment of telomeres and aging hallmarks.\n* Receive an integrative approach combining Traditional Chinese Medicine (TCM), targeted nutritional support, and standard fertility care.\n* Proceed with natural conception attempts or standard assisted reproductive technologies following the preconception phase.\n* Participants will be followed to assess pregnancy outcomes and changes in biological aging hallmarks.",[88,89,28,27,90],"Idiopathic Infertility","Infertility Unexplained","Infertility Female",[92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115],"Telomere dysfunction","Telomere attrition","Telomere biology","Cellular aging","Mitochondrial dysfunction","Cellular senescence","Reproductive aging","Functional infertility","Idiopathic infertility","Post-treatment unexplained infertility","Oocyte quality","Endometrial receptivity","Biomarkers of reproductive quality","Single-cell FISH","Leukocyte telomere length","Molecular etiology of infertility","Aging hallmarks","Traditional Chinese Medicine","Integrative fertility therapy","Nutraceutical support","Mitochondrial biogenesis","Oxidative stress","Reproductive resilience","Beyond Genomix","2026-04-28",{"date":118,"type":40},"2026-04-29",{"date":120,"type":40},"2025-01-01",{"date":122,"type":20},"2026-12-01",{"name":124,"class":125},"BEYOND GENOMiX SA, AG, Ltd","INDUSTRY",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":58,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100633972","prospective-international-multi-center-clinical-trial-of-pgt-a-upgrade-100633972","NCT07533630","Prospective International Multi-center Clinical Trial of PGT-A Upgrade","Efficacy of PGT-A Upgrade in Preimplantation Genetic Testing of Embryos: An International Multicenter Prospective Clinical Study","Inclusion Criteria:\n\n(1) Any one of the following conditions being met is sufficient:\n\n1. advanced maternal age (AMA, age ≥35 years),\n2. recurrent implantation failure (RIF),\n3. recurrent miscarriage (RM),\n4. severe male factor (SMF). (2) And at least one blastocyst is available.\n\nExclusion Criteria:\n\n1. Couples undergoing PGT-SR due to chromosomal structural abnormalities carried by either one or both members, such as balanced translocations, Robertsonian translocations, inversions, complex chromosomal rearrangements, and pathogenic microdeletions or microduplications;\n2. Couples undergoing PGT-M;\n3. Conditions with established impact on uterine morphology or endometrial receptivity, including untreated uterine malformations (septate uterus, unicornuate uterus, didelphic uterus, etc.) and untreated hydrosalpinx;\n4. Embryos coming from oocyte or sperm (gametes) donation;\n5. Individuals with contraindications to pregnancy or assisted reproduction technology.","20 Years","46 Years",{"count":136,"type":20},1700,"The goals of this international multicenter cross-sectional study are:\n\n1. To provide patients with a comprehensive PGT solution capable of simultaneously detecting embryonic chromosomal aneuploidy, mosaicism, microdeletions\u002F microduplications, heteroploidy, and heterozygosity (LOH) in a single assay, thereby reducing miscarriage and birth defects;\n2. To perform PGT analysis on abnormally fertilized embryos, select euploid embryos with normal ploidy, and calculate embryo utilization rates;\n3. To reduce the false-positive rate through confirmation of mosaic embryos and subsequent analysis of its origin, thereby minimizing embryo wastage;\n4. To provide molecular genetic evidence for expert consensus on clinical management of atypically fertilized embryos, of pathogenic\u002Flikely pathogenic small CNVs, optimize mosaic embryo transfer strategies, and inform preconception intervention;\n5. To enhance international PGT testing standards through international multi-center collaboration.\n\nThe study will enroll patients undergoing PGT-A from seven domestic and international centers, with patient enrollment expected to be completed within one year. PGT-A upgrade testing will be performed on embryos from enrolled patients, and the incidence rates of Incidence of microdeletions\u002Fmicroduplications, heteroploidy, LOH will be statistically analyzed. All patients who undergo embryo transfer will be followed up for clinical outcomes and birth defects.",[27],[140,141,142],"Preimplantation Genetic Testing for Aneuploidies","Mosaic embryos","Microdeletions\u002Fmicroduplications","NOT_YET_RECRUITING","2026-04-09",{"date":146,"type":40},"2026-04-16",{"date":148,"type":20},"2026-05",{"date":150,"type":20},"2028-08",{"name":152,"class":47},"Reproductive & Genetic Hospital of CITIC-Xiangya",7,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":58,"minAge":16,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":174,"locationsCount":48},"100628952","egg-donation-at-the-assisted-reproductive-technology-art-center-of-the-nancy-university-hospital-100628952","NCT07468331","Egg Donation at the Assisted Reproductive Technology (ART) Center of the Nancy University Hospital","DONOVO-Nancy: Egg Donation at the Assisted Reproductive Technology (ART) Center of the Nancy University Hospital: an Overview of the Donor Journey Since the Revisions to the Bioethics Laws","DONOVO-Nancy","Inclusion Criteria:\n\n* All women who attended a biological consultation for primary or secondary oocyte donation at Nancy University Hospital during the study period.\n\nExclusion Criteria:\n\n* Absence of biological consultation for oocyte donation during the study period ;\n* Insufficient or missing medical data ;\n* Documented opposition to data use for research purposes.","38 Years",{"count":164,"type":20},60,"Since the 2021 revision of French bioethics laws, access to assisted reproductive technologies (ART) has expanded, leading to a significant increase in gamete donation requests. In this context, oocyte donation remains a limited resource, with marked disparities between centers and persistent donor shortages.\n\nAt the Assisted Reproductive Technology Center of Nancy University Hospital, more than fifty women have initiated an oocyte donation process since the implementation of the new legislation. However, not all candidates complete the donation pathway, and clinical and organizational outcomes have not yet been formally evaluated.\n\nThis retrospective observational study will evaluate the oocyte donation pathway at the Assisted Reproductive Technology Center of Nancy University Hospital. The study population will include all women who attended a biological consultation for primary or secondary oocyte donation from the implementation of the new Bioethics laws until December 31, 2025 (study period).\n\nBaseline clinical and biological characteristics of donor candidates will be described, including age, body mass index, anti-Müllerian hormone level, and antral follicle count.\n\nThe proportion of donor candidates undergoing oocyte retrieval and the time interval between the first biological consultation and oocyte retrieval will be assessed.\n\nBiological and clinical outcomes will also be analyzed, including the number of oocytes retrieved, the number of mature oocytes (metaphase II) obtained, fertilization rate following in vitro fertilization, clinical pregnancy rate per embryo transfer, and live birth rate.\n\nResults will be compared with national data reported by the French Biomedicine Agency in order to evaluate the activity and outcomes of the center and to identify potential areas for organizational and clinical improvement in the oocyte donation pathway.\n\nThe overall objective is to optimize donor management and improve access to oocyte donation for recipient patients.",[167,27],"Egg Donation","2026-03-11",{"date":170,"type":40},"2026-03-12",{"date":172,"type":20},"2026-03",{"date":148,"type":20},{"name":175,"class":47},"Central Hospital, Nancy, France",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":58,"minAge":16,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":186,"conditions":187,"keywords":193,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":48},"100621860","effects-of-infertility-and-assisted-reproductive-technology-on-sexual-function-and-behavior-100621860","NCT07376109","Effects of Infertility and Assisted Reproductive Technology on Sexual Function and Behavior","Effect of Infertility and Assisted Reproductive Technology (ART) on Sexual Function and Behaviour","Inclusion Criteria:\n\n1. Assigned female at birth.\n2. Self-identify as a woman.\n3. Age 18-44 years.\n4. Diagnosis of infertility.\n5. Seeking fertility treatment at the MUHC Reproductive Centre.\n\nExclusion Criteria:\n\n1. Assigned male at birth.\n2. Age 45 years or older.\n3. Sexual practices that do not allow for the possibility of conception (e.g., same-sex relationships without use of assisted reproductive technologies).\n4. Seeking oocyte cryopreservation.\n5. Individuals who do not wish to complete the anonymous questionnaire.","44 Years",{"count":185,"type":20},500,"This cross-sectional observational study examines how infertility and the use of assisted reproductive technology (ART) are related to sexual function and sexual behaviors in women seeking fertility treatment. Infertility and the stress of ART may be associated with changes in sexual desire, satisfaction, and activity. The purpose is to better understand these associations to support the sexual health and overall well-being of women undergoing fertility care.\n\nWomen who are assigned female at birth, under 45 years old, diagnosed with infertility, and attending appointments at the MUHC Reproductive Centre are invited to take part. Participants will be asked to complete an anonymous questionnaire while waiting for their clinical visit. The questionnaire includes the validated Female Sexual Function Index (FSFI), which measures different aspects of sexual function, and additional questions about sexual activities, such as frequency of intercourse and other behaviors before and after fertility treatments.\n\nParticipants will not provide any identifying information. Completed questionnaires will be placed in a secure collection box to protect confidentiality.\n\nData from approximately 500 participants will be analyzed to explore how infertility type (primary vs. secondary), duration of infertility, and the number of unsuccessful ART cycles relate to sexual function and behavior. Findings from this study may help healthcare providers better recognize and address the sexual health concerns of women with infertility.\n\nThis study is approved by the McGill University Health Centre Research Ethics Board (REB #2025-11459).",[27,188,189,190,191,26,192],"Sexual Behavior","Sexual Function","Sexual Dysfunction and Infertility","Sexual Dysfunction Female","Assisted Reproductive Techniques",[194,31,195,196,197,198,199,200,201,202],"infertility","ART","IVF","female sexual function","female sexual function index","FSFI","sexual behavior","sexual dysfunction","women's sexual health","2026-02-19",{"date":205,"type":40},"2026-02-20",{"date":207,"type":40},"2026-02-06",{"date":209,"type":20},"2027-01",{"name":211,"class":47},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":58,"minAge":16,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":21,"phases":223,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":48},"100620598","a-prospective-study-to-evaluate-the-outcome-of-the-aurora-test-used-with-blastocyst-transfer-in-an-icsi-cycle-aurora-blasto-100620598","NCT07359703","A Prospective Study to Evaluate the Outcome of the Aurora Test Used With Blastocyst Transfer in an ICSI Cycle (Aurora-Blasto)","A Prospective Study to Evaluate the Outcome of the Aurora Test Used With Blastocyst Transfer in an ICSI Cycle","Aurora-Blasto","Inclusion Criteria:\n\n1. Patients undergoing ICSI treatment, with maximum 40 years of age at time of signing the ICF\n2. Patients stimulated with GnRH antagonist\u002FHP-hMG or GnRH antagonist\u002FrecFSH, scheduled for fresh SET Day 5 with hCG or dual trigger (hCG + GnRH agonist) or Patients stimulated with GnRH antagonist\u002FHP-hMG or GnRH antagonist\u002FrecFSH, scheduled for delayed transfer of frozen\u002Fthawed SET Day 5 after a GnRH agonist trigger, hCG or dual trigger (hCG + GnRH agonist).\n3. Patients undergoing a first, second, third or fourth ICSI cycle\n4. Women with body mass index (BMI) higher than 17 and lower than 35\n5. Women with regular cycles (between 24 and 35 days)\n6. Non-and mild-smokers (\\\u003C10 cigarettes\u002Fday)\n7. AMH 1,1 ng\u002Fml (Bologna criteria), excluding poor responders according to Bologna criteria\n8. Patients with fresh ejaculated semen or frozen donor semen\n\nExclusion Criteria:\n\n1. Patients with less than 8 follicles (≥12mm) on the day of their last echo visit before OPU.\n2. Women with history of poor oocyte maturation in a previous cycle (\\\u003C 50% MII)\n3. Women with Severe Endometriosis (≥ III AFS classification) (in the ovaries and if not surgically treated)\n4. Patients scheduled for PGD (preimplantation genetic diagnosis of monogenic\u002Fsingle gene defects) and PGT-A (preimplantation genetic testing on aneuploidy)\n5. Couples where the partner has an extremely low sperm count e.g.: severe oligo-astheno-teratozoospermia (OAT) with sperm count below 100.000\u002Fml or TESE.","40 Years",{"count":222,"type":20},1028,[23],"In current treatments for In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI), the creation of multiple embryos is a common practice. The decision to transfer an embryo is traditionally based on the morphological assessment by an embryologist, which, due to its nature, must be considered subjective. In certain regions, invasive embryo biopsy techniques, such as Preimplantation Genetic Testing for Aneuploidy (PGT-A), are used to detect chromosomal abnormalities and support decision-making regarding embryo transfer. However, there is a medical need to improve the outcomes of IVF\u002FICSI cycles through non-invasive and objective methods.\n\nAs an academic center, our goal is to investigate promising innovative methods that, if successful, can be integrated into standard care. The aim of the Aurora blastocyst study is to evaluate the effectiveness of the Aurora test in selecting five-day-old embryos for fresh or frozen embryo transfer. Additionally, the study assesses whether the use of the Aurora test results in an increase in clinical pregnancy rates and live birth rates.\n\nThe Aurora test is a non-invasive test for evaluating oocyte competence and subsequently the embryo obtained in an ICSI cycle (In Vitro Fertilization). This test is performed on cumulus cells (CC) surrounding the oocyte and uses mRNA expression profiles to evaluate the developmental potential of the oocytes. The test has been developed and validated for patients stimulated with human menopausal gonadotropins (HP-hMG), an ovulatory dose of hCG, and a single embryo transfer on day 3. The test will be performed by Fertiga nv, upon receiving patients cumulus cells.\n\nAt our center, based on earlier research, the standard care involves a single embryo transfer on day 5. In this study, embryo selection based on morphology is compared with embryo selection based on morphology and the Aurora test. Finally, this study aims to evaluate the impact of the Aurora test score on the embryologist's selection decision for transferring a five-day-old embryo for single embryo transfer, by assessing parameters such as pregnancy rates and live birth rates.",[27],[195],"2026-01-15",{"date":229,"type":40},"2026-01-22",{"date":231,"type":40},"2025-10-15",{"date":233,"type":20},"2029-06-01",{"name":235,"class":47},"University Hospital, Ghent",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":58,"minAge":16,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100618739","the-efficacy-of-remimazolam-on-incidence-of-hypoxia-during-sedated-transvaginal-oocyte-retrieval-a-multicenter-randomized-controlled-trial-100618739","NCT07335536","The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.","Inclusion Criteria:\n\n* Subjects aged 18 to 50 years planning to undergo painless oocyte retrieval\n* Subjects classified as American Society of Anesthesiologists (ASA) physical status I-II\n\nExclusion Criteria:\n\n* Subjects with contraindications to general anesthesia, acute or severe cardiovascular disease history, acute upper respiratory infection, chronic obstructive pulmonary disease (COPD), asthma attacks, or uncontrolled hypertension\n* Subjects with alcohol abuse\n* Subjects with severe hepatic or renal insufficiency, severe cardiovascular disease, or psychiatric disorder history\n* Subjects with hearing impairment preventing communication\n* Subjects with a history of long-term sedative or opioid use, or allergies to benzodiazepines, flumazenil, opioids and their antidotes, propofol, eggs, or soy products\n* Subjects with SpO2 \\\u003C 95% while breathing room air after entering the room","50 Years",{"count":244,"type":20},400,[23],"Hypoxia is the most common adverse reaction during sedation outside the operating room.Exploring novel drug combinations to reduce the incidence of hypoxia during sedation in patients undergoing transvaginal oocyte retrieval procedures enhances patient safety and lowers perioperative adverse event rates. This multicenter, prospective, randomized, controlled clinical study will compare the hypoxia incidence rate of the remimazolam-alfentanil combination against the commonly used propofol-alfentanil combination.",[248,26,27],"Hypoxia",[248,250,251,252],"oocyte retrieval","remimazolam","general anesthesia","2026-01-01",{"date":255,"type":40},"2026-01-13",{"date":257,"type":40},"2025-10-20",{"date":259,"type":20},"2026-12-30",{"name":261,"class":47},"Diansan Su",3,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":58,"minAge":16,"maxAge":162,"enrollmentInfo":271,"targetDuration":4,"studyType":21,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100611421","first-line-surgery-or-first-line-fertility-treatment-using-assisted-reproductive-technologies-in-patients-with-advanced-endometriosis-100611421","NCT07240363","First Line Surgery or First Line Fertility Treatment Using Assisted Reproductive Technologies in Patients With Advanced Endometriosis","First Line Surgery or First Line Fertility Treatment Using Assisted Reproductive Technologies in Patients With Advanced Endometriosis: A National Multicenter Randomized-controlled Trial","EndoSOFT","Inclusion Criteria:\n\n* Age 18 - 38 years old\n* Endometriosis AAGL stage III-IV\n* Referred or eligible for ART-treatment such as IVF or ICSI, independent of infertility diagnosis (28) (including sperm donation cycles for social reasons) and\u002For infertility due to dyspareunia\u002Fdysmenorrhea caused by endometriosis\n* Body mass index 18-35 kg\u002Fm2\n* Patients who have signed an approved Informed Consent\n\nExclusion Criteria:\n\n* Previous surgery for endometriosis except diagnostic laparoscopy.\n* Previous IVF\u002FICSI-cycles (including prior fertility preservation cycles)\n* Hemato- and\u002For hydrosalpinx\n* Clear indication for surgery such as ureteral stenosis or intestinal sub-occlusive symptoms\n* Suspicion of malignancy\n* Submucosal fibroids (The International Federation of Gynecology and Obstetrics (FIGO) 0-1, any size) or intramural fibroids (FIGO 2-5, \\> 4 cm largest diameter of the largest myoma) (29)\n* Uterine malformations (class U1-U6 according to ESHRE\u002FESGE-classification) (30)\n* Patients with contraindications to surgery\n* Patients undergoing ART with donated oocytes",{"count":272,"type":20},350,[23],"Endometriosis is a chronic disease affecting approximately 10% of women of reproductive age. It is strongly associated with pelvic pain and infertility. Women with advanced stages of the disease (stage III-IV) have markedly reduced fertility compared with the general population. A Swedish study has shown that about 22% of women undergoing treatments with assisted reproductive technologies (ART), such as in vitro fertilization (IVF), are affected by endometriosis.\n\nThe optimal management of women with advanced endometriosis and infertility remains uncertain. Some clinicians advocate proceeding directly to IVF, while others suggest surgical removal of endometriosis lesions prior to IVF in order to improve the chances of pregnancy. Currently, evidence is limited to a small number of observational studies. Two observational studies and one meta-analysis have suggested that surgery before IVF in women with deep endometriosis may increase both pregnancy and live birth rates compared with IVF alone. However, no randomized controlled trial (RCT) has yet been conducted to answer this important clinical question.\n\nThis study will be the first national multicenter randomized controlled trial to compare surgery followed by IVF with IVF alone in women with advanced endometriosis and infertility. All Swedish centers for highly specialized endometriosis surgery and fertility treatment will participate.\n\nEligible participants are women under 39 years of age with stage III-IV endometriosis who seek fertility treatment. Participants will be randomized in a 1:1 ratio to one of two groups:\n\n* Surgery prior to IVF (laparoscopic excision of endometriosis lesions, followed by IVF).\n* Direct IVF without prior surgery. The primary outcome is the cumulative live birth rate within three years of randomization and initiation of the allocated treatment. Secondary outcomes include pregnancy rates, time to pregnancy, treatment-related complications, patient-reported quality of life, and cost-effectiveness.\n\nOur hypothesis is that surgery before IVF will lead to a higher cumulative live birth rate compared with IVF without prior surgery in women with advanced endometriosis.\n\nThe results of this trial are expected to have significant impact on clinical practice and international guidelines. Regardless of outcome, the study will provide robust evidence to guide treatment strategies, improve the care of women with advanced endometriosis and infertility, and potentially reduce healthcare costs by identifying the most effective pathway to achieving pregnancy.",[276,27],"Endometriosis",[276,26,278,195],"Surgery","2025-11-16",{"date":281,"type":40},"2025-11-20",{"date":283,"type":40},"2025-10-06",{"date":285,"type":20},"2031-09-22",{"name":287,"class":47},"Karolinska Institutet",4,{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":57,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":21,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100561222","fertishare-evaluation-100561222","NCT06587360","fertiShare Evaluation","Protocol for a Realist Evaluation and Feasibility RCT: Understanding and Developing a SPIKES-based eLearning Training Course Called fertiShare to Support Sharing Bad News Encounters Between Fertility Healthcare Professionals (FHPs) and Patients","Fertility Healthcare Professionals' inclusion criteria are:\n\n* working at participating clinics; and\n* whose role involves a minimum of 10% of week time (half a day) SBN or being a non-clinical decision-maker (e.g., clinic\u002Fline managers).\n\nPatients' inclusion criteria are\n\n• adult individuals or couples attending participating clinics to discuss or undergo (in)fertility diagnosis or treatment with participating FHPs.\n\nExclusion criteria are:\n\n* not being able to read, speak or understand English;\n* not being able to provide consent.\n* for FHPs only, being unable to undergo the fertiShare training (e.g., visual impairments).\n\nWe will not be targeting groups or individuals deemed vulnerable. Potential participants are explicitly informed in the information sheet that, if they are worried about their mental health or psychological wellbeing they may chose not to participate at all. They are also advised to inform their fertility team and contact their GP in the usual way or the NHS Mental Health support service, www.nhs.yj\u002Fmental-health.",{"count":297,"type":20},420,[23],"Sharing bad news (SBN) is a daily challenge for fertility staff and patients. Bad news happens at all stages of fertility care and includes e.g., diagnosing infertility, reporting unexpected, repeated, or definitive treatment failure. Extensive evidence shows that SBN triggers stress in staff due to anticipation of negative emotions and evaluations or, in extreme cases, even complaints and lawsuits. Inability to manage bad news can increase negative emotions in patients and fuel distrust, potentially leading to treatment discontinuation. Efficient SBN training exists but does not address challenges of SBN in fertility care, does not meet fertility staff training and patient care preferences, and its impact on patients is unclear.\n\nfertiShare is a brief, evidence-based, e-Learning SBN course bespoke for fertility care. The aim of the study is to evaluate the feasibility of implementing fertiShare at fertility clinics and of implementing an online multi-centre RCT to determine fertiShare's efficacy. This will allow to conclude if fertiShare should proceed to efficacy evaluation.\n\nAn international interdisciplinary stakeholder group (patients, consultants, embryologists, nurses, psychologists, digital educators) will inform all aspects of the proposed project.",[27],[302,303,304,194],"sharing bad news","healthcare communication","assisted reproduction","2025-07-24",{"date":307,"type":40},"2025-07-29",{"date":309,"type":40},"2024-10-08",{"date":311,"type":20},"2026-02-28",{"name":313,"class":47},"Cardiff University",5,{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":15,"minAge":133,"maxAge":220,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":48},"100573169","the-feasibility-of-tavns-on-pregnancy-outcomes-of-infertility-patients-undergoing-ivf-100573169","NCT06742788","The Feasibility of taVNS on Pregnancy Outcomes of Infertility Patients Undergoing IVF","The Feasibility of Transcutaneous Auricular Vagus Nerve Stimulation on Pregnancy Outcomes of Infertility Patients Undergoing in Vitro Fertilization: Study Protocol for a Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Subjects aged 20 to 40 years, diagnosed with infertility, and preparing to undergo IVF treatment;\n2. Female subjects with anti-Müllerian hormone (AMH) \\> 1.2 ng\u002FmL;\n3. Scoring at mild-to-moderate levels of impairment on anxiety, and depression scales;\n4. Both the subject and their family sign the informed consent form.\n\nExclusion Criteria:\n\n1. The subject had been treated with taVNS in the past;\n2. Subjects preparing to undergo frozen embryo transfer;\n3. Subjects with a history of mental disorder or who score at a severe level of impairment on anxiety and depression scales;\n4. Taking sedatives, anxiety, depression, or psychiatric medications;\n5. Comorbidities including arrhythmia, hypertension, diabetes, chronic heart and kidney diseases;\n6. Ineligibility for enrollment assessed by a gynecologist or neurologist;\n7. Metallic implants or devices contraindicating taVNS.",{"count":323,"type":20},90,[23],"To assess the feasibility of taVNS on pregnancy outcomes of infertility subjects undergoing IVF, the primary aim of this trial will focus on encompassing recruitment, compliance, and preliminary engagement outcomes.\n\nThe exploratory aim is to carry out clinical research, which entails evaluating the preliminary effects of the intervention in order to ascertain its potential benefits.\n\nThe main question it aims to answer is: Does the taVNS is feasible and tolerated in the context of IVF?\n\nWhat medical problems do participants have when using the taVNS device? Researchers will compare the taVNS to the sham transcutaneous auricular vagus nerve stimulation (a look-alike device that produces a sub-threshold therapeutic stimulus and functions as a sham stimulus) and blank control to see if the taVNS device works to enhance outcomes of IVF.\n\nParticipants will:\n\nUse the device a total of 1.5 hours daily, with the sessions divided into three parts, each lasting 30 minutes. At least one of these periods occur within 2 hours before bedtime.\n\nVisit the clinic according to the scheduled treatment time points of IVF. Keep a diary of their adverse events and the number of times they use the device.",[27],[26,192,328],"Transcutaneous Auricular Vagus Nerve Stimulation","2025-06-26",{"date":331,"type":40},"2025-07-02",{"date":333,"type":40},"2025-03-04",{"date":335,"type":20},"2025-12-30",{"name":337,"class":47},"Xijing Hospital",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":58,"minAge":16,"maxAge":242,"enrollmentInfo":346,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":48},"100591804","phase-4-does-the-addition-of-letrozole-to-ultra-long-gnrh-agonists-help-adenomyosis-patients-in-art-the-aura-trial-100591804","NCT06985186","Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial","The Effect of Adenomyosis Following Ultra-long GnRH Agonists With or Without Aromatase Inhibitors on ART Outcomes (AURA Trial): a Randomized Controlled Trial","AURA","Inclusion Criteria:\n\n\\- Infertile patients affected by adenomyosis diagnosed by 2D-3D transvaginal ultrasound according to revised Morphological Uterus Sonographic Assessment consensus.\n\nExclusion Criteria:\n\n* concomitant uterine fibroids,\n* Müllerian malformations,\n* endometrial pathology,\n* thin endometrium,\n* hydrosalpinx,\n* mucometra,\n* previous surgery except for previous cesarean section,\n* coagulation disorders,\n* untreated endocrinopathies,\n* severe seminal pathologies,\n* double ET,\n* ET different from the first one after adenomyosis treatment.",{"count":347,"type":20},162,[349],"PHASE4","The AURA Trial seeks to improve fertility treatment for women affected by a condition known as adenomyosis. Adenomyosis often leads to heavy menstrual bleeding, pelvic pain, dyspareunia and can make it more difficult to achieve and maintain a healthy pregnancy.\n\nIn this randomized controlled trial participating women ≥ 18 years of age with a confirmed imaging diagnosis of adenomyosis according to Morphological Uterus Sonographic Assessment (MUSA) consensus will first undergo a thorough assessment. This initial workup includes reviewing medical history, assessing the characteristics of the uterus (volume, myometrial architecture, shape of the uterine cavity, stiffness, etc.) via 2D\u002F3D transvaginal ultrasound, and obtaining blood tests to establish baseline hormone levels.\n\nOnce enrolled, each participant will be assigned at random-without prior knowledge by either the woman or her care team-to one of two 90-day pre-treatment regimens. The first group will receive monthly injections of a GnRH agonist, a medication that temporarily suppresses ovarian function and lowers estrogen levels. The second group will follow the same injection schedule but will also take daily letrozole tablets, an aromatase inhibitor that further reduces estrogen production. The hope is that this combined approach will calm the inflammatory environment caused by adenomyosis, promote a more receptive uterus, and ultimately increase the likelihood of an embryo developing beyond the critical 12-week mark.\n\nAt the end of the 90-day protocol, and after repeating all evaluations carried out during the enrolment phase, all women will proceed with the planned assisted reproductive technology cycle with the usual careful monitoring until the day of emrbyo transfer. To ensure correct interpretation of the results and to minimise the potential effect of any incompetent oocytes, only euploid embryos evaluated by pre-implantation genetic test or embryos derived from donated oocytes will be transferred. Pregnancy will be assessed first with a blood test, followed by an ultrasound scan at approximately six or seven weeks to confirm a clinical pregnancy. An ongoing pregnancy, defined by the detection of the fetal heartbeat beyond the 12th week, is the main measure of success.\n\nBy participating in AURA, women and their families not only gain access to cutting-edge clinical care but also contribute valuable knowledge that could shape future standard treatments for adenomyosis-related infertility. For further information or to explore participation, please reach out to the Instituto Bernebu Assisted Reproduction Center, where our team is ready to guide you through every step of this important study.",[352,27],"Adenomyosis of Uterus",[354,194,355,356,357,358,359],"adenomyosis","Ultra-Long GnRH Agonists","Aromatase inhibitor","IVF outcomes","assisted reproductive technology","egg-donation","2025-05-22",{"date":362,"type":40},"2025-05-29",{"date":364,"type":20},"2025-06",{"date":366,"type":20},"2026-12",{"name":368,"class":47},"University of Palermo",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":58,"minAge":16,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":21,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":392,"locationsCount":48},"100565027","language-matters-exploring-the-impact-of-language-concordance-on-fertility-treatment-progression-100565027","NCT06636838","Language Matters: Exploring the Impact of Language Concordance on Fertility Treatment Progression","ImpaLa","Inclusion Criteria:\n\n* Must be greater than 18 years old\n* Preferred language must be Spanish speaking\n* Must be seeking fertility treatment\n\nExclusion Criteria:\n\n* Preferred language English\n* Not currently seeking fertility care\n* Less than 18 years old",{"count":377,"type":20},70,[23],"Currently, patients presenting to the Fertility and Reproductive Medicine Center meet with an English-speaking provider and communicate through an interpreter, as none of the physicians speak Spanish. However, this study PI is a native Spanish speaker and certified bilingual clinician. Thus, this study is looking to evaluate whether or not the use of an interpreter delays completion of testing and initiation of fertility treatment. The medically indicated testing, procedures, and course of treatment will not be altered as a result of participation in the study. Participants will be asked to complete a survey in their preferred language to gauge satisfaction and communication efficacy.\n\nThis proposed study is significant as it seeks to address a critical gap in the understanding of how language concordance between healthcare providers and patients influences treatment outcomes in fertility care. With Spanish being the most commonly spoken non-English language in the U.S., evaluating the impact of Spanish language skills in medical care is both timely and essential. This research will shed light on whether Spanish-speaking patients experience better treatment progression and outcomes when cared for by language-concordant providers versus when interpreters are used in fertility care.\n\nThis prospective study will be conducted at Washington University's Fertility and Reproductive Medicine Center over a 12-month period. The investigators aim to enroll a total of 70 Spanish-speaking patients, based on previous patient trends at the Center 35 will be randomized to the intervention group (being evaluated and treated by a Spanish-speaking provider), and 35 will be randomized to standard of care (communicating with an English-speaking provider through an interpreter).",[26,28,27,381],"Ovulation Ind",[383,384,194,385,196],"Spanish speaking","Spanish","Infertility work-up","2025-03-24",{"date":388,"type":40},"2025-03-28",{"date":390,"type":40},"2024-10-15",{"date":335,"type":20},{"name":393,"class":47},"Washington University School of Medicine",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":58,"minAge":16,"maxAge":242,"enrollmentInfo":401,"targetDuration":4,"studyType":21,"phases":403,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":48},"100574442","the-effect-of-stress-ball-used-during-intra-uterine-insemination-on-pain-anxiety-comfort-and-physiological-parameters-100574442","NCT06759337","The Effect of Stress Ball Used During Intra Uterine Insemination on Pain, Anxiety, Comfort and Physiological Parameters","The Effect of Stress Ball Used During Intra Uterine Insemination on Pain, Anxiety, Comfort and Physiological Parameters: A Randomized Controlled Study","Inclusion Criteria:\n\nIntervention Group 1 (Stress Ball Group)\n\n1. Agreeing to participate in the study with verbal and written consent,\n2. Being between the ages of 18-50,\n3. Being able to read and write in Turkish,\n4. Not having a muscle or joint problem that prevents squeezing the stress ball\n5. Having Intrauterine Insemination (insemination) as an infertility treatment,\n\nIntervention Group 2 (Hand Holding Group)\n\n1. Agreeing to participate in the study with verbal and written consent,\n2. Being between the ages of 18-50,\n3. Being able to read and write in Turkish,\n4. Not having a problem with holding hands\n5. Having Intrauterine Insemination (insemination) as an infertility treatment,\n\nControl Group\n\n1. Agreeing to participate in the study with verbal and written consent,\n2. Being between the ages of 18-50,\n3. Being able to read and write in Turkish,\n4. Having Intrauterine Insemination (insemination) as an infertility treatment, To have an insemination (vaccination) procedure,\n\nExclusion Criteria:\n\nIntervention Group (Stress Ball Group)\n\n1. Use any analgesic agent at least 24 hours before the procedure,\n2. Having a chronic pain disorder,\n3. Abandoning the completion of the data collection forms,\n4. Needing urgent intervention by a physician during or immediately after the procedure,\n5. Having any psychiatric disease,\n6. Having a visual, hearing, speech, physical or mental disability,\n7. Wanting to leave the study at any stage,\n8. Not applying the stress ball application as requested\n\nIntervention Group (Hand Holding Group)\n\n1. Use any analgesic agent at least 24 hours before the procedure,\n2. Having a chronic pain disorder,\n3. Being uncomfortable with the hand-holding application,\n4. Abandoning the completion of the data collection forms,\n5. Needing urgent intervention by a physician during or immediately after the procedure,\n6. Having any psychiatric disease,\n7. Having visual, hearing, speech, having a physical or mental disability,\n8. Wanting to leave the study at any stage,\n\nControl Group\n\n1. Use any analgesic agent at least 24 hours before the procedure,\n2. Having a chronic pain disorder,\n3. Stopping the completion of the data collection forms,\n4. Needing urgent intervention by a physician during or immediately after the procedure,\n5. Having any psychiatric disease,\n6. Having a visual, hearing, speech, physical or mental disability,\n7. Wanting to leave the study at any stage,",{"count":402,"type":20},120,[23],"This study aimed to determine the effects of holding the patient's hand and using a stress ball during the Intrauterine Insemination procedure on pain, anxiety, comfort, and physiological parameters. This study will be conducted as a randomized controlled trial with a pre-test-post-test procedure in the IVF Unit of a Medical Faculty Hospital in Turkey. The study sample was planned to include 120 participants, 40 women each in the stress ball, hand-holding, and control groups. Data will be collected using the Personal Information Form, Visual Analog Scale, State Anxiety Inventory, and General Comfort Scale Short Form. In the Stress Ball Group, participants are given a colored silicone stress ball (5-7 cm diameter) 5 minutes before the procedure. During the procedure, they are instructed to squeeze the ball twice after counting to 10 and repeat this until the procedure is complete. In the Hand-Holding Group, the researcher holds one of the participant's hands during catheter insertion and removal. The researcher's fingers are closed but not interlocked and placed gently on the participant's hand without additional movements or gloves. In the Control Group, Participants receive no additional intervention beyond the standard routine procedures.",[27,406],"Infertility, Female",[192,408,409,410,411,412,194],"Stress Ball","Pain","Anxiety","Comfort","Physiological Parameters","2024-12-28",{"date":415,"type":40},"2025-01-06",{"date":417,"type":40},"2024-10-01",{"date":419,"type":20},"2025-06-30",{"name":421,"class":47},"TC Erciyes University",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":58,"minAge":133,"maxAge":220,"enrollmentInfo":429,"targetDuration":431,"studyType":62,"phases":4,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":4},"100572848","difference-between-progestin-primed-ovarian-stimulation-protocol-and-antagonist-protocol-100572848","NCT06738602","Difference Between Progestin Primed Ovarian Stimulation Protocol and Antagonist Protocol","Comparison Between Progestin Primed Ovarian Stimulation Protocol and Antagonist Protocol in Hyper-responder Patients Schaduled for Freeze All Policy","Inclusion Criteria:\n\n• All hyper responder patients according to Olivera equation for overian response peridiction index\n\nExclusion Criteria:\n\n* All normal and poor responder patients according to Olivera equation for overian response peridiction index.\n* Sever male factor infertility",{"count":430,"type":20},270,"12 Months","compare the effectiveness and safety of the progestin primed ovarian stimulation (PPOS) protocol versus the antagonist protocol in hyper-responder patients scheduled for a freeze-all policy",[27],[435],"progestin primed ovarian stimulation","2024-12-13",{"date":438,"type":40},"2024-12-17",{"date":440,"type":20},"2024-12-30",{"date":442,"type":20},"2027-12-30",{"name":444,"class":47},"Assiut University"]